Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxad088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Naoki Kamegai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Peritoneum, Peritonitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Alzheimer's Society, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Peritonitis and the resulting peritoneal injuries are common problems that prevent long-term peritoneal dialysis (PD) therapy in patients with end-stage kidney diseases. Previously, we have analyzed the relationship between the complement system and progression of peritoneal injuries associated with PD, particularly focusing on the early activation pathways and effects of the anaphylatoxins. We here utilized a novel mAb 2H2 that blocks assembly of the membrane attack complex (MAC) to investigate roles of the complement terminal pathway in PD-associated peritoneal injury. We intraperitoneally injected mAb 2H2 anti-C5b-7 (2.5 or 5 mg/rat) once or twice over the five-day course of the experiment to investigate the effects of inhibiting formation of MAC in a fungal rat peritonitis model caused by repeated intraperitoneal administration of zymosan after methylglyoxal pretreatment (Zy/MGO model). Rats were sacrificed on day 5 and macroscopic changes in both parietal and visceral peritoneum evaluated. Peritoneal thickness, the abundance of fibrinogen and complement C3 and MAC deposition in tissue and accumulation of inflammatory cells were pathologically assessed. The results showed that mAb 2H2, but not isotype control mAb, reduced peritoneal thickness and accumulation of inflammatory cells in a dose and frequency-dependent manner in the Zy/MGO model. These effects were accompanied by decreased C3, MAC, and fibrinogen deposition in peritoneum. In conclusion, in the rat Zy/MGO model, complement terminal pathway activation and MAC formation substantially contributed to development of peritoneal injuries, suggesting that MAC-targeted therapies might be effective in preventing development of peritoneal injuries in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Division of Infection and Immunity, and Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, UK.
ORCID-Profile: B Paul Morgan, Masashi Mizuno
Förderung
- Medical Research Council
- Alzheimer's Society
- Ministry of Education, Culture, Sports, Science and Technology
- Japanese Association of Dialysis Physicians
- Aichi Kidney Foundation
- Japanese Society for Peritoneal Dialysis
- UK Dementia Research Institute
- Alzheimer’s Society
Zitieren
APA
Kamegai, N., Kim, H., Suzuki, Y., Fukui, S., Kojima, H., Maruyama, S., Morgan, B. P., Zelek, W. M., & Mizuno, M. (2023). Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad088
Vancouver
Kamegai N, Kim H, Suzuki Y, Fukui S, Kojima H, Maruyama S, et al. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad088
BibTeX
@article{Kamegai2023,
author = {Kamegai, Naoki and Kim, Hangsoo and Suzuki, Yasuhiro and Fukui, Sosuke and Kojima, Hiroshi and Maruyama, Shoichi and Morgan, B Paul and Zelek, Wioleta Milena and Mizuno, Masashi},
title = {Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxad088}
}
EUVIMED